Literature DB >> 2985258

Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.

A F Gazdar, D N Carney, M M Nau, J D Minna.   

Abstract

We have described the establishment and biochemical characterization of 50 small cell lung carcinoma (SCLC) cell lines. Further analysis of these data, combined with studies of morphology and growth characteristics, indicates that 35 (70%) of the lines retained typical morphology (SCLC, intermediate subtype), growth characteristics (growth as tightly packed floating cellular aggregates, long doubling times and low colony-forming efficiencies), and biochemical profile (presence of L-dopa decarboxylase, bombesin-like immunoreactivity, neuron-specific enolase, and high concentrations of brain isoenzyme of creatine kinase). They are referred to as classic SCLC lines. The remaining 15 (30%) lines had discordant expression of the biochemical markers; they retained high concentrations of brain isozyme of creatine kinase, but had significantly lower concentrations of neuron-specific enolase and lacked L-dopa decarboxylase and bombesin-like immunoreactivity. These cell lines are called variants. SCLC variant lines could further be divided into (a) biochemical variant lines having variant biochemical profile but retaining typical SCLC morphology and growth characteristics; and (b) morphological variant (SCLC-MV) lines having variant biochemical profile, altered morphology (features of large cell undifferentiated carcinoma) and altered growth characteristics (growth as loosely attached floating aggregates, relatively short doubling times and cloning efficiencies). Fifty-five clones derived from the three SCLC subclasses retained their parental phenotypes. In SCLC-MV lines there was a near constant relationship between variant morphology, altered growth characteristics and amplification of the c-myc oncogene; classic SCLC and biochemical variant SCLC lines were not amplified. Variant morphologies frequently are present in SCLC tumors at autopsy, and most SCLC-MV lines reflect changes that had occurred in the tumors from which they were derived. Because SCLC-MV tumors behave more virulently in the patient and are radioresistant in vitro, these findings are of considerable biological and clinical interest.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985258

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  139 in total

Review 1.  Serum-free culture of carcinoma cell lines.

Authors:  P Collodi; C Rawson; D Barnes
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

2.  GLI3 encodes a 190-kilodalton protein with multiple regions of GLI similarity.

Authors:  J M Ruppert; B Vogelstein; K Arheden; K W Kinzler
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

3.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

Authors:  Gurkan Mollaoglu; Matthew R Guthrie; Stefanie Böhm; Johannes Brägelmann; Ismail Can; Paul M Ballieu; Annika Marx; Julie George; Christine Heinen; Milind D Chalishazar; Haixia Cheng; Abbie S Ireland; Kendall E Denning; Anandaroop Mukhopadhyay; Jeffery M Vahrenkamp; Kristofer C Berrett; Timothy L Mosbruger; Jun Wang; Jessica L Kohan; Mohamed E Salama; Benjamin L Witt; Martin Peifer; Roman K Thomas; Jason Gertz; Jane E Johnson; Adi F Gazdar; Robert J Wechsler-Reya; Martin L Sos; Trudy G Oliver
Journal:  Cancer Cell       Date:  2017-01-12       Impact factor: 31.743

4.  Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).

Authors:  Megumi Furuta; Jun Sakakibara-Konishi; Hajime Kikuchi; Hiroshi Yokouchi; Hiroshi Nishihara; Hiroyuki Minemura; Masao Harada; Shigeo Yamazaki; Kenji Akie; Yuka Fujita; Kei Takamura; Tetsuya Kojima; Toshiyuki Harada; Yoshinori Minami; Naomi Watanabe; Satoshi Oizumi; Hiroyuki Suzuki; Masaharu Nishimura; Hirotoshi Dosaka-Akita; Hiroshi Isobe
Journal:  Oncologist       Date:  2019-05-08

5.  Immunotargeting of human small cell lung cancer xenografts in athymic mice using a monoclonal antibody (RNL-1) against a neuroendocrine-related antigen.

Authors:  E P Mijnheere; O C Boerman; J L Broers; M Klein Rot; G P Vooijs; F C Ramaekers
Journal:  Br J Cancer Suppl       Date:  1991-06

6.  Human calcitonin gene regulation by helix-loop-helix recognition sequences.

Authors:  D W Ball; D Compton; B D Nelkin; S B Baylin; A de Bustros
Journal:  Nucleic Acids Res       Date:  1992-01-11       Impact factor: 16.971

7.  Tetanus toxin as a marker for small-cell lung cancer cell lines.

Authors:  J Heymanns; K Neumann; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

8.  Human small-cell lung cancers show amplification and expression of the N-myc gene.

Authors:  M M Nau; B J Brooks; D N Carney; A F Gazdar; J F Battey; E A Sausville; J D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

9.  Oncogene overexpression in non-small-cell lung cancer tissue: prevalence and clinicopathological significance.

Authors:  J Lorenz; T Friedberg; R Paulus; F Oesch; R Ferlinz
Journal:  Clin Investig       Date:  1994-01

10.  Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: can we predict the response to chemotherapy in small cell lung cancer?

Authors:  J L Moretti; M Caglar; C Boaziz; N Caillat-Vigneron; J F Morere
Journal:  Eur J Nucl Med       Date:  1995-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.